Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Q3 2024 value amounting to $109.2 million.

  • Rhythm Pharmaceuticals' Non-Current Deffered Revenue rose 433.82% to $109.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $109.2 million, marking a year-over-year increase of 433.82%. This contributed to the annual value of $106.1 million for FY2023, which is 4001.19% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Non-Current Deffered Revenue of $109.2 million as of Q3 2024, which was up 433.82% from $108.4 million recorded in Q2 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Non-Current Deffered Revenue registered a high of $109.2 million during Q3 2024, and its lowest value of $3.0 million during Q1 2020.
  • Moreover, its 4-year median value for Non-Current Deffered Revenue was $104.7 million (2023), whereas its average is $85.7 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Non-Current Deffered Revenue soared by 4001.19% in 2023 and then soared by 433.82% in 2024.
  • Quarter analysis of 4 years shows Rhythm Pharmaceuticals' Non-Current Deffered Revenue stood at $3.0 million in 2020, then surged by 2462.01% to $75.8 million in 2022, then surged by 40.01% to $106.1 million in 2023, then grew by 2.92% to $109.2 million in 2024.
  • Its Non-Current Deffered Revenue stands at $109.2 million for Q3 2024, versus $108.4 million for Q2 2024 and $107.4 million for Q1 2024.